Alere Shareholders Approve Amended Merger with Abbott

7/8/17

Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced that its shareholders have voted to approve the previously announced amended merger with Abbott. In a final count of the voting results, approximately 63 million of votes cast at a special meeting voted in favor of the amended merger, representing over 72.5% of all outstanding Alere shares as of the May 31, 2017 record date. The final vote results will be filed on a Form 8-K with the Securities and Exchange Commission.

Upon closing of the merger, Alere shareholders will receive $51 per common share in cash, and Alere will become a subsidiary of Abbott. The transaction remains subject to the satisfaction of customary closing conditions, including applicable regulatory approvals.

About Alere

Alere believes that when diagnosing and monitoring health conditions, Knowing now matters.™Alere delivers reliable and actionable information by providing rapid diagnostic tests, enhancing clinical and economic healthcare outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for cardiometabolic disease, infectious disease and toxicology. For more information on Alere, please visit www.alere.com.

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.